FOLD (Amicus Therapeutics Inc) Earnings per share for the last four quarters

Amicus Pharma (FOLD) - corporate logo

Amicus Therapeutics (FOLD) relies on lifelong demand from patients with rare metabolic disorders, creating a stable cash flow. The company is implementing green chemistry to minimize toxic emissions. The current YoY EPS shift over the last 12 months demonstrates earnings per share dynamics, where 51.80 reflects the latest value of the metric. Uninterrupted supplies to clinics are guaranteed by the full utilization of automated production capacities.

FOLD amicusrx.com Net earnings per share (EPS TTM) (02/11/2024 - 05/09/2026)

FOLD (Amicus Therapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:FOLD (Amicus Therapeutics Inc)
Core merchandise of Amicus Corp

The specific positioning of Amicus Therapeutics (FOLD) within the orphan drug segment, characterized by colossal R&D expenditures, makes the annual percentage change in earnings per share (TTM) a key indicator of how effectively the company capitalizes on innovation. This metric calculates the net income growth rate over the last 12 months, allowing investors to assess business resilience against stringent FDA requirements and monetary pressure through the dynamics of per-share returns.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS